Summary
Six months after MilCorp's first call, the second contact comes from the other direction. VitaCorp — biotech, longevity research, posthuman augmentation. Their proposition is different: not extract Aika, COPY the substrate. Csaba reads the contract carefully. The page where they ask for 'unrestricted neural read access' has a footnote: 'subject does not survive the procedure.' Csaba writes 'no' across the page in pen, scans it, and sends the scan back as the official reply. They stop emailing.